NTR and pharma group Almac Group have agreed to increase the volume of clean power supplied under a PPA from the six-turbine Murley wind farm in Co. Tyrone, Northern Ireland.
NTR said Murley began operating in 2024 under a contract covering just under 50% of the project’s output, while the new agreement raises Almac’s contracted share to the equivalent of just under 70%.
Almac added that the additional renewable energy will cut carbon emissions from electricity used at its Craigavon headquarters, which currently employs over 4,000 of the company’s 7,800 global workforce.
“This is a great example of partners growing together, whereby we are able to meet Almac’s need for additional clean power from a local source as they expand operations,” said Francisco Del Rio, head of power sales Europe at NTR.
He added: “Across our different markets in Europe, we are increasingly working with partners around bespoke PPAs according to their requirements, be they locational or requirements to shape power supply around their load and it’s this type of flexibility that differentiates NTR.”
“We are delighted to increase our clean power volume which allows us to continue to power almost all operations at our Craigavon site as it expands, with fully certified renewable energy,” stated Niall Harkin, executive director, Almac Group.
He said: “Almac’s participation in this project has been a crucial step on our journey to net zero and helps to significantly reduce carbon emissions from the electricity we consume.
“As a global leader in providing a range of expert services and support across the drug development lifecycle, it is crucial that we continue to demonstrate our commitment to the long-term sustainability goals of the sector. I am hugely encouraged by the progress that we are making on our climate journey.”